Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageOmada Health, Inc. (together with its subsidiary and consolidated professional corporation, the “Company” or “Omada”) offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal (“MSK”) conditions; additional support for members taking glucagon-like peptide-1 agonists (“GLP-1”) in its cardiometabolic programs (“GLP-1 Care Tracks”); and behavioral health support across all programs.
In the company’s own words · 10-K filed Mar 6, 2026 · SEC EDGAR
Business segments
Jun 2026 · $87.8MThe company’s own SEC segment disclosure.
- Service$80.7M92%
- Hardware$7.1M8%
Omada Health, Inc. (OMDA) reported revenue of $78M in Q1 2026 (quarter ended Mar 31, 2026), up 42% from the same quarter a year earlier. That came with a gross margin of 62% and net loss of $3.0M. For the full year FY2025, revenue was $260M (+53% year on year) and net income −$13M. Its largest product in Jun 2026 was Service at $81M, 92% of the disclosed total, well ahead of Hardware at 8.1%.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.
Health Information Services
Ranks #11 of 13 by Smart Score